GlaxoSmithKline: Phase III Trial Of MAGE-A3 Fails To Meet Co-primary Endpoints

(RTTNews) - GlaxoSmithKline plc (GSK.L, GSK) announced the analysis of the MAGRITi trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticii in non-small cell lung cancer patients, showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population (first co-primary endpoint) or in those MAGE-A3-positive patients who did not receive chemotherapy (second co-primary endpoint).

The Independent Data Monitoring Committee indicated that its review of the current safety information raised no specific concern for the continuation of the trial. GSK said it will continue the trial in order to assess the third co-primary endpoint. Results from a final analysis are expected in 2015. MAGRIT, a randomised, double-blind, placebo-controlled trial, is evaluating the efficacy and safety of the MAGE-A3 cancer immunotherapeutic in Stage IB, II and IIIA completely resected NSCLC patients whose tumours expressed the MAGE-A3 gene.